

## Inc. Names Lillian Chiang to Its 2026 Female Founders 500 List

*Inc.'s annual Female Founders list celebrates the nation's most innovative women entrepreneurs, who collectively generated approximately \$12.3 billion in 2025*

**Doylestown, PA, March 10, 2026** – Evrys Bio, Inc is proud to announce that our CEO, Lillian Chiang, Ph.D., has been named to Inc.'s [2026 Female Founders 500](#), an annual list honoring the most dynamic women business leaders in the United States. The honor recognizes founders whose bold ideas, resilience, and execution are shaping the future of their industries.

The 2026 Female Founders honorees collectively generated approximately \$12.3 billion in 2025 revenue and \$12.2 billion in funding to date, underscoring the economic impact of women-led businesses across sectors.

Each year, Inc. editors evaluate applications through a rigorous, multi-round selection process. Founders are assessed on both quantitative performance metrics, including revenue growth, funding, sales, and audience size, as well as qualitative factors such as innovation, social impact, and brand momentum. The final list represents entrepreneurs who have demonstrated exceptional leadership and measurable progress over the past year. Previous honorees have included such game-changing leaders as Billie Jean King, Sallie Krawcheck, Serena Williams, and Emma Grede — all of whom have transformed their industries and broken barriers along the way.

It's an honor to be recognized alongside so many remarkable women founders. Breakthrough innovation comes from bold ideas and diverse leadership, and I'm excited to keep building and contributing to that momentum said Lillian Chiang.

Honoree selection is also honed through the evaluation of the program's advisory board, which includes Patty Arvielo, co-founder and CEO of New American Funding; Tiffany Dufu, president of the Tory Burch Foundation; Joy Mangano, co-founder and CEO of CleanBoss; Michelle Cordeiro Grant, founder and CEO of GORGIE; Sheila Lirio Marcelo, co-founder and CEO of Ohai.ai and founder of Care.com; and Melissa Mash, co-founder and CEO of Dagne Dover.

Lillian Chiang is an accomplished entrepreneur and technology leader known for building innovative companies at the intersection of science, data, and healthcare. As a founder and CEO, she has led the development of cutting-edge platforms that apply advanced analytics and computational approaches to complex biological challenges. Under her leadership, her company has attracted strong industry interest, built strategic collaborations, and advanced technologies designed to accelerate discovery and improve the development of next-generation therapeutics.

Beyond company building, Chiang has played an active role in the broader innovation ecosystem, working with leading researchers, investors, and industry partners to translate breakthrough science into real-world impact. She is widely recognized for her ability to bridge scientific insight with entrepreneurial execution, assembling high-performing teams and guiding early-stage technologies from concept toward commercialization. Her recognition on the 2026 Female Founders 500 List reflects both her leadership in advancing innovative technology and her commitment to expanding opportunities for the next generation of founders.

"Each year, we are increasingly amazed by the extraordinary leaders on our Inc. Female Founders 500 list," says Bonny Ghosh, editorial director at Inc. "The honorees on this year's list include innovators in AI, beauty and wellness trendsetters winning devoted fans, and nonprofit leaders making a real impact in their communities. Together, they're showing all of us what trailblazing female leadership looks like."

Several honorees will be featured in *Inc.* magazine's Spring print issue, on newsstands March 17, 2026. To see the complete list of honorees, please visit: <https://www.inc.com/female-founders/2026>.

#### **About Inc.**

Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit [www.inc.com](http://www.inc.com).

#### **About Evrys Bio, Inc**

**Evrys Bio** is a biotechnology company developing novel host-targeted therapeutics for viral diseases. Evrys is developing safe and effective, first-in-class therapies that can simultaneously treat a broad spectrum of viruses, while preventing drug-resistance. By modulating SIRT2 activity, Evrys aims to reprogram host cellular pathways required for viral replication and persistence. Evrys is advancing a pipeline of potent, selective, allosteric inhibitors of SIRT2 to address serious viral infections with significant unmet medical need.